Every one of those 1 sits in a single category, regulation. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Duchenne muscular dystrophy
Every one of those 1 sits in a single category, regulation. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. Duchenne muscular dystrophy appears in 1 tracked Legal story from March 10, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 38 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Duchenne muscular dystrophy. Shared-story counts are live from our verified record — not editorial picks.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.